Celon Pharma files for marketing authorization of semaglutide injection (Ozempic equivalent)

Polish pharma Celon Pharma submitted marketing authorization applications for a semaglutide injection, an Ozempic biosimilar/generic. This is a regulatory step, not a market launch; approval timelines and commercial impact are uncertain. It signals potential competition in the GLP-1 market, but the immediate market effect is limited.